Literature DB >> 29510988

Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma.

Presha Rajbhandari1,2, Gonzalo Lopez1,3, Claudia Capdevila1, Beatrice Salvatori1, Jiyang Yu1,4, Ruth Rodriguez-Barrueco5,6, Daniel Martinez3, Mark Yarmarkovich3, Nina Weichert-Leahey7, Brian J Abraham8, Mariano J Alvarez1, Archana Iyer1, Jo Lynne Harenza3, Derek Oldridge3, Katleen De Preter9, Jan Koster10, Shahab Asgharzadeh11,12, Robert C Seeger11,12, Jun S Wei13, Javed Khan13, Jo Vandesompele9, Pieter Mestdagh9, Rogier Versteeg10, A Thomas Look7, Richard A Young8,14, Antonio Iavarone15, Anna Lasorella16, Jose M Silva5, John M Maris17,18,19, Andrea Califano20,21,22,23.   

Abstract

High-risk neuroblastomas show a paucity of recurrent somatic mutations at diagnosis. As a result, the molecular basis for this aggressive phenotype remains elusive. Recent progress in regulatory network analysis helped us elucidate disease-driving mechanisms downstream of genomic alterations, including recurrent chromosomal alterations. Our analysis identified three molecular subtypes of high-risk neuroblastomas, consistent with chromosomal alterations, and identified subtype-specific master regulator proteins that were conserved across independent cohorts. A 10-protein transcriptional module-centered around a TEAD4-MYCN positive feedback loop-emerged as the regulatory driver of the high-risk subtype associated with MYCN amplification. Silencing of either gene collapsed MYCN-amplified (MYCNAmp) neuroblastoma transcriptional hallmarks and abrogated viability in vitro and in vivo Consistently, TEAD4 emerged as a robust prognostic marker of poor survival, with activity independent of the canonical Hippo pathway transcriptional coactivators YAP and TAZ. These results suggest novel therapeutic strategies for the large subset of MYCN-deregulated neuroblastomas.Significance: Despite progress in understanding of neuroblastoma genetics, little progress has been made toward personalized treatment. Here, we present a framework to determine the downstream effectors of the genetic alterations sustaining neuroblastoma subtypes, which can be easily extended to other tumor types. We show the critical effect of disrupting a 10-protein module centered around a YAP/TAZ-independent TEAD4-MYCN positive feedback loop in MYCNAmp neuroblastomas, nominating TEAD4 as a novel candidate for therapeutic intervention. Cancer Discov; 8(5); 582-99. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 517. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29510988      PMCID: PMC5967627          DOI: 10.1158/2159-8290.CD-16-0861

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  81 in total

1.  Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3.

Authors:  A L Gartel; X Ye; E Goufman; P Shianov; N Hay; F Najmabadi; A L Tyner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Expression of the cdc25B mRNA correlated with that of N-myc in neuroblastoma.

Authors:  Y Sato; H Sasaki; S Kondo; I Fukai; M Kiriyama; Y Yamakawa; Y Fujii
Journal:  Jpn J Clin Oncol       Date:  2001-09       Impact factor: 3.019

3.  Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma.

Authors:  Jason M Shohet; M John Hicks; Sharon E Plon; Susan M Burlingame; Susan Stuart; Si-Yi Chen; Malcolm K Brenner; Jed G Nuchtern
Journal:  Cancer Res       Date:  2002-02-15       Impact factor: 12.701

4.  ArrayCGH-based classification of neuroblastoma into genomic subgroups.

Authors:  Evi Michels; Jo Vandesompele; Katleen De Preter; Jasmien Hoebeeck; Joëlle Vermeulen; Alexander Schramm; Jan J Molenaar; Björn Menten; Barbara Marques; Raymond L Stallings; Valérie Combaret; Christine Devalck; Anne De Paepe; Rogier Versteeg; Angelika Eggert; Geneviève Laureys; Nadine Van Roy; Frank Speleman
Journal:  Genes Chromosomes Cancer       Date:  2007-12       Impact factor: 5.006

5.  The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.

Authors:  Susan L Cohn; Andrew D J Pearson; Wendy B London; Tom Monclair; Peter F Ambros; Garrett M Brodeur; Andreas Faldum; Barbara Hero; Tomoko Iehara; David Machin; Veronique Mosseri; Thorsten Simon; Alberto Garaventa; Victoria Castel; Katherine K Matthay
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

6.  Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma.

Authors:  Tobias Otto; Sebastian Horn; Markus Brockmann; Ursula Eilers; Lars Schüttrumpf; Nikita Popov; Anna Marie Kenney; Johannes H Schulte; Roderick Beijersbergen; Holger Christiansen; Bernd Berwanger; Martin Eilers
Journal:  Cancer Cell       Date:  2009-01-06       Impact factor: 31.743

7.  Most random gene expression signatures are significantly associated with breast cancer outcome.

Authors:  David Venet; Jacques E Dumont; Vincent Detours
Journal:  PLoS Comput Biol       Date:  2011-10-20       Impact factor: 4.475

8.  Inferring tumour purity and stromal and immune cell admixture from expression data.

Authors:  Kosuke Yoshihara; Maria Shahmoradgoli; Emmanuel Martínez; Rahulsimham Vegesna; Hoon Kim; Wandaliz Torres-Garcia; Victor Treviño; Hui Shen; Peter W Laird; Douglas A Levine; Scott L Carter; Gad Getz; Katherine Stemke-Hale; Gordon B Mills; Roel G W Verhaak
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

9.  Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.

Authors:  L L Wang; R Teshiba; N Ikegaki; X X Tang; A Naranjo; W B London; M D Hogarty; J M Gastier-Foster; A T Look; J R Park; J M Maris; S L Cohn; R C Seeger; S Asgharzadeh; H Shimada
Journal:  Br J Cancer       Date:  2015-06-02       Impact factor: 7.640

10.  Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers.

Authors:  Ruth Rodriguez-Barrueco; Jiyang Yu; Laura P Saucedo-Cuevas; Mireia Olivan; David Llobet-Navas; Preeti Putcha; Veronica Castro; Eva M Murga-Penas; Ana Collazo-Lorduy; Mireia Castillo-Martin; Mariano Alvarez; Carlos Cordon-Cardo; Kevin Kalinsky; Matthew Maurer; Andrea Califano; Jose M Silva
Journal:  Genes Dev       Date:  2015-07-30       Impact factor: 11.361

View more
  43 in total

Review 1.  Hippo pathway effectors YAP and TAZ and their association with skeletal muscle ageing.

Authors:  Iwan Setiawan; Ardo Sanjaya; Ronny Lesmana; Paul M Yen; Hanna Goenawan
Journal:  J Physiol Biochem       Date:  2021-01-26       Impact factor: 4.158

2.  A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors.

Authors:  Mariano J Alvarez; Prem S Subramaniam; Laura H Tang; Adina Grunn; Mahalaxmi Aburi; Gabrielle Rieckhof; Elena V Komissarova; Elizabeth A Hagan; Lisa Bodei; Paul A Clemons; Filemon S Dela Cruz; Deepti Dhall; Daniel Diolaiti; Douglas A Fraker; Afshin Ghavami; Daniel Kaemmerer; Charles Karan; Mark Kidd; Kyoung M Kim; Hee C Kim; Lakshmi P Kunju; Ülo Langel; Zhong Li; Jeeyun Lee; Hai Li; Virginia LiVolsi; Roswitha Pfragner; Allison R Rainey; Ronald B Realubit; Helen Remotti; Jakob Regberg; Robert Roses; Anil Rustgi; Antonia R Sepulveda; Stefano Serra; Chanjuan Shi; Xiaopu Yuan; Massimo Barberis; Roberto Bergamaschi; Arul M Chinnaiyan; Tony Detre; Shereen Ezzat; Andrea Frilling; Merten Hommann; Dirk Jaeger; Michelle K Kim; Beatrice S Knudsen; Andrew L Kung; Emer Leahy; David C Metz; Jeffrey W Milsom; Young S Park; Diane Reidy-Lagunes; Stuart Schreiber; Kay Washington; Bertram Wiedenmann; Irvin Modlin; Andrea Califano
Journal:  Nat Genet       Date:  2018-06-18       Impact factor: 38.330

3.  miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma.

Authors:  Holly Holliday; Jessica Yang; Eoin Dodson; Iva Nikolic; Alvin Kamili; Madeleine Wheatley; Niantao Deng; Sarah Alexandrou; Thomas P Davis; Maria Kavallaris; C Elizabeth Caldon; Joshua McCarroll; Katleen De Preter; Pieter Mestdagh; Glenn M Marshall; Kaylene J Simpson; Jamie Fletcher; Alexander Swarbrick
Journal:  Mol Ther       Date:  2022-01-05       Impact factor: 11.454

4.  Super enhancers define regulatory subtypes and cell identity in neuroblastoma.

Authors:  Moritz Gartlgruber; Ashwini Kumar Sharma; Andrés Quintero; Daniel Dreidax; Carl Herrmann; Frank Westermann; Selina Jansky; Young-Gyu Park; Sina Kreth; Johanna Meder; Daria Doncevic; Paul Saary; Umut H Toprak; Naveed Ishaque; Elena Afanasyeva; Elisa Wecht; Jan Koster; Rogier Versteeg; Thomas G P Grünewald; David T W Jones; Stefan M Pfister; Kai-Oliver Henrich; Johan van Nes
Journal:  Nat Cancer       Date:  2020-12-07

5.  Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.

Authors:  Balakrishna Koneru; Gonzalo Lopez; Ahsan Farooqi; Karina L Conkrite; Thinh H Nguyen; Shawn J Macha; Apexa Modi; Jo Lynne Rokita; Eduardo Urias; Ashly Hindle; Heather Davidson; Kristyn Mccoy; Jonas Nance; Vanda Yazdani; Meredith S Irwin; Shengping Yang; David A Wheeler; John M Maris; Sharon J Diskin; C Patrick Reynolds
Journal:  Cancer Res       Date:  2020-04-14       Impact factor: 12.701

6.  YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling.

Authors:  Grace E Coggins; Alvin Farrel; Komal S Rathi; Colin M Hayes; Laura Scolaro; Jo Lynne Rokita; John M Maris
Journal:  Cancer Res       Date:  2019-10-31       Impact factor: 12.701

7.  Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy.

Authors:  Marie-Eve Beaulieu; Toni Jauset; Daniel Massó-Vallés; Sandra Martínez-Martín; Peter Rahl; Loïka Maltais; Mariano F Zacarias-Fluck; Sílvia Casacuberta-Serra; Erika Serrano Del Pozo; Christopher Fiore; Laia Foradada; Virginia Castillo Cano; Meritxell Sánchez-Hervás; Matthew Guenther; Eduardo Romero Sanz; Marta Oteo; Cynthia Tremblay; Génesis Martín; Danny Letourneau; Martin Montagne; Miguel Ángel Morcillo Alonso; Jonathan R Whitfield; Pierre Lavigne; Laura Soucek
Journal:  Sci Transl Med       Date:  2019-03-20       Impact factor: 17.956

8.  Lats1/2 Sustain Intestinal Stem Cells and Wnt Activation through TEAD-Dependent and Independent Transcription.

Authors:  Qi Li; Yang Sun; Gopala K Jarugumilli; Shun Liu; Kyvan Dang; Jennifer L Cotton; Jordi Xiol; Pui Yee Chan; Michael DeRan; Lifang Ma; Rui Li; Lihua J Zhu; Joyce H Li; Andrew B Leiter; Y Tony Ip; Fernando D Camargo; Xuelian Luo; Randy L Johnson; Xu Wu; Junhao Mao
Journal:  Cell Stem Cell       Date:  2020-04-06       Impact factor: 24.633

9.  A modular master regulator landscape controls cancer transcriptional identity.

Authors:  Evan O Paull; Alvaro Aytes; Sunny J Jones; Prem S Subramaniam; Federico M Giorgi; Eugene F Douglass; Somnath Tagore; Brennan Chu; Alessandro Vasciaveo; Siyuan Zheng; Roel Verhaak; Cory Abate-Shen; Mariano J Alvarez; Andrea Califano
Journal:  Cell       Date:  2021-01-11       Impact factor: 41.582

Review 10.  Bone Marrow Environment in Metastatic Neuroblastoma.

Authors:  Chiara Brignole; Fabio Pastorino; Patrizia Perri; Loredana Amoroso; Veronica Bensa; Enzo Calarco; Mirco Ponzoni; Maria Valeria Corrias
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.